Biotech Values

[dewophile]

absolutely
and what is suggested in vitro may not translate in vivo
and even though drugs may interact in terms of bioactivity when given concurrently, doesn't mean thay can't be given sequentially (like vx-950 prove trial)
and does rib interaction even matter given that peg-nm283 alone has shown superior results to peg-rib in phase II
still many unanswered questions
Of note..seems that the current interaction study is more of a pk rather than pd study based on what i heard in the question/answer session of today's webcast (i was focusing more on efficacy). given the renal excretion of nm-283 it's almost certain not to interact with rib metabolism, and therefore there will almost definitely be a triple therapy arm in phase III to assess efficacy from what i gather